271 related articles for article (PubMed ID: 25429316)
21. Viral hepatitis and hepatocellular carcinoma.
Michielsen PP; Francque SM; van Dongen JL
World J Surg Oncol; 2005 May; 3():27. PubMed ID: 15907199
[TBL] [Abstract][Full Text] [Related]
22. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.
Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ
JHEP Rep; 2022 Oct; 4(10):100552. PubMed ID: 36119722
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology and surveillance of hepatocellular carcinoma.
Kim DY; Han KH
Liver Cancer; 2012 Jun; 1(1):2-14. PubMed ID: 24159567
[TBL] [Abstract][Full Text] [Related]
24. Changing epidemiology of hepatocellular carcinoma in Asia.
Goh GB; Chang PE; Tan CK
Best Pract Res Clin Gastroenterol; 2015 Dec; 29(6):919-28. PubMed ID: 26651253
[TBL] [Abstract][Full Text] [Related]
25. Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Wang MD; Li C; Liang L; Xing H; Sun LY; Quan B; Wu H; Xu XF; Wu MC; Pawlik TM; Lau WY; Shen F; Yang T
Oncologist; 2020 Oct; 25(10):e1541-e1551. PubMed ID: 32472951
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma.
Kew MC
Pathol Biol (Paris); 2010 Aug; 58(4):273-7. PubMed ID: 20378277
[TBL] [Abstract][Full Text] [Related]
27. Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection.
Wu HC; Jeng WJ; Pan MH; Hsieh YC; Lu SN; Chen CJ; Yang HI
JHEP Rep; 2022 Feb; 4(2):100410. PubMed ID: 35079699
[TBL] [Abstract][Full Text] [Related]
28. Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide.
Palliyaguru DL; Wu F
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2013; 30(3):534-40. PubMed ID: 23281740
[TBL] [Abstract][Full Text] [Related]
29. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.
Liu Y; Wu F
Environ Health Perspect; 2010 Jun; 118(6):818-24. PubMed ID: 20172840
[TBL] [Abstract][Full Text] [Related]
30. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach.
Sylla A; Diallo MS; Castegnaro J; Wild CP
Mutat Res; 1999 Jul; 428(1-2):187-96. PubMed ID: 10517992
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity.
Kirk GD; Turner PC; Gong Y; Lesi OA; Mendy M; Goedert JJ; Hall AJ; Whittle H; Hainaut P; Montesano R; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):373-9. PubMed ID: 15734960
[TBL] [Abstract][Full Text] [Related]
32. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review.
Alavian SM; Haghbin H
Hepat Mon; 2016 Mar; 16(3):e35106. PubMed ID: 27226803
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.
Mbaga DS; Kenmoe S; Kengne-Ndé C; Ebogo-Belobo JT; Mahamat G; Foe-Essomba JR; Amougou-Atsama M; Tchatchouang S; Nyebe I; Feudjio AF; Kame-Ngasse GI; Magoudjou-Pekam JN; Fokou LKM; Meta-Djomsi D; Maïdadi-Foudi M; Touangnou-Chamda SA; Daha-Tchoffo AG; Selly-Ngaloumo AA; Nayang-Mundo RA; Yéngué JF; Taya-Fokou JB; Kenfack-Momo R; Atembeh Noura E; Demeni Emoh CP; Tazokong HR; Bowo-Ngandji A; Sake CS; Atenguena Okobalemba E; Njiki Bikoi J; Njouom R; Riwom Essama SH
PLoS One; 2022; 17(1):e0262903. PubMed ID: 35061846
[TBL] [Abstract][Full Text] [Related]
34. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide.
Zidan A; Scheuerlein H; Schüle S; Settmacher U; Rauchfuss F
Hepat Mon; 2012 Oct; 12(10 HCC):e6894. PubMed ID: 23233864
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
Patmore LA; van Eekhout KMA; Buti M; Koc ÖM; Agarwal K; de Knegt RJ; Janssen HLA; van der Valk M; Lieveld FI; Hansen BE; Kramer M; de Bruijne J; Claassen MAA; Smit C; de Man RA; Takkenberg B; Carey I; Sonneveld MJ;
J Hepatol; 2024 Feb; 80(2):243-250. PubMed ID: 37898348
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.
Lodato F; Mazzella G; Festi D; Azzaroli F; Colecchia A; Roda E
World J Gastroenterol; 2006 Dec; 12(45):7239-49. PubMed ID: 17143937
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B virus-related hepatocellular carcinoma presenting at an advanced stage: is it preventable?
Mules T; Gane E; Lithgow O; Bartlett A; McCall J
N Z Med J; 2018 Nov; 131(1486):27-35. PubMed ID: 30496164
[TBL] [Abstract][Full Text] [Related]
38. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
Kirk GD; Lesi OA; Mendy M; Szymañska K; Whittle H; Goedert JJ; Hainaut P; Montesano R
Oncogene; 2005 Sep; 24(38):5858-67. PubMed ID: 16007211
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma: an epidemiologic view.
El-Serag HB
J Clin Gastroenterol; 2002; 35(5 Suppl 2):S72-8. PubMed ID: 12394209
[TBL] [Abstract][Full Text] [Related]
40. Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia.
Nguyen VT; Amin J; Law MG; Dore GJ
J Gastroenterol Hepatol; 2009 Mar; 24(3):436-42. PubMed ID: 19175834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
